Survival of lymphocytes is not restricted by IDO-expressing fibroblast from rheumatoid arthritis patients

Massalska, Magdalena; Kuca-Warnawin, Ewa; Janicka, Iwona; Plebańczyk, Magdalena; Pawlak, Dariusz; Dallos, Tomáš; Olwert, Anna; Radzikowska, Anna; Małdyk, Paweł; Kontny, Ewa; Maśliński, Włodzimierz

doi:10.1080/08923973.2019.1569048

Cited by 3 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, IDO overexpression has been detected in the RA synovial, as well as in OA synovial. Under the inflamed synovium microenvironment, the expression of IDO was evaluated at a mRNA level in human FLS isolated from RA patients ( Massalska et al, 2019 ). Some studies have found that IDO expression showed a direct effect on RA-related chondrocytes proliferation and collagen II in the matrix that suggests a possible effect on the MMPs ( Chang et al, 2018 ).…”

Section: Therapeutic Enzymes and Their Derivatives In Ramentioning

confidence: 99%

Research Progress of Therapeutic Enzymes and Their Derivatives: Based on Herbal Medicinal Products in Rheumatoid Arthritis

Cai

Han

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) acts as one of the most common, agnogenic and chronic inflammatory-autoimmune disorder which is characterized by persistent synovitis, cartilage destruction, and joint deformities, leads to a wide range of disabilities, and increased mortality, thus imposing enormous burdens. Several drugs with anti-inflammatory and immunomodulatory properties such as celecoxib, diclofenac and methotrexate are being selected as conventional drugs in the allopathic system of medicine for the treatment of RA in clinic. However, there are some serious side effects more or less when using these drugs because of their short poor bioavailability and biological half-life for a long time. These shortcomings greatly promote the exploration and application of new low- or no-toxicity drugs for treating the RA. Meanwhile, a growing number of studies demonstrate that several herbs present certain anti-inflammatory and anti-arthritic activities through different enzymes and their derivatives, which indicate that they are promising therapeutic strategies when targeting these mediators based on herbal medicinal products in RA research. This review article summarizes the roles of the main enzymes and their derivatives during the pathogenesis of RA, and clearly clarifies the explicit and potential targeted actions of herbal medicinal products that have anti-RA activity. Our review provides timely and critical reference for the scientific rationale use of herbal medicinal products, with the increasing basic research and clinical application of herbal medicinal products by patients with RA.

show abstract

Section: Therapeutic Enzymes and Their Derivatives In Ramentioning

confidence: 99%

Research Progress of Therapeutic Enzymes and Their Derivatives: Based on Herbal Medicinal Products in Rheumatoid Arthritis

Cai

Han

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“… 31 , 32 RA fibroblast-like synoviocytes (FLS), the main effector cells in joint destruction and perpetuation of inflammation in RA, were able to produce IDO as a result of IFN-γ stimulation. 33 , 34 The recent data showed that JAKi (tofacitinib (TOFA), BARI, and upadacitinib (UPA)) significantly suppressed the expression of IDO by FLS and decreased IDO-mediated suppressive effects of FLS on T cell proliferation. 35 Observed effects resulted probably from suppression of IFN-γ secretion as well as IFN-γ signalling by JAKi.…”

Section: Potential Mechanism Of Fatiguementioning

confidence: 99%

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases

Felis-Giemza,

Massalska,

Roszkowski

et al. 2023

JIR

Self Cite

View full text Add to dashboard Cite

It is well known that fatigue is a highly disabling symptom commonly observed in inflammatory rheumatic diseases (IRDs). Fatigue is strongly associated with a poor quality of life and seems to be an independent predictor of job loss and disability in patients with different rheumatic diseases. Although the pathogenesis of fatigue remains unclear, indirect data suggest the cooperation of the immune system, the central and autonomic nervous system, and the neuroendocrine system in the induction and sustainment of fatigue in chronic diseases. Fatigue does not correspond with disease activity and its mechanism in IRDs. It is suggested that it may change over time and vary between individuals. Abnormal production of pro-inflammatory cytokines such as interleukin-6 (IL-6), interferons (IFNs), granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF, IL-15, IL-17 play a role in both IRDs and subsequent fatigue development. Some of these cytokines such as IL-6, IFNs, GM-CSF, and common gamma-chain cytokines (IL-15, IL-2, and IL-7) activate the Janus Kinases (JAKs) family of intracellular tyrosine kinases. Therapy blocking JAKs (JAK inhibitors -JAKi) has been recently proven to be an effective approach for IRDs treatment, more efficient in pain reduction than anti-TNF. Therefore, the administration of JAKi to IRDs patients experiencing fatigue may find rational implications as a therapeutic modulator not only of disease inflammatory symptoms but also fatigue with its components like pain and neuropsychiatric features as well. In this review, we demonstrate the latest information on the mechanisms of fatigue in rheumatic diseases and the potential effect of JAKi on fatigue reduction. Plain Language Summary• JAKi block pro-inflammatory cytokines, decrease activation of IDO, diminish the effects of genetic polymorphism (particularly mediated by IL-6 and IL-1β) as well as sickness behavior also connected with IL-1β expression, which result in fatigue and pain inhibition. • In patients treated with JAKi, it was observed that there was significantly greater improvement compared to placebo and MTX in fatigue and pain reduction measured using PROs. • Administration of JAKi (BARI+UPA) benefits over TNFi treatment in pain and fatigue reduction assessed by PtGA in RA patients. • The effectiveness of fatigue reduction in PROs under recently approved JAKi still needs to be proven in clinical practice, especially in selective and nonselective groups of JAKi.

show abstract

“…Overexpression of WRS in T cells from patients with RA is apparently related to the pathogenesis of this disease. Although IDO is overexpressed in DCs in the synovial joints of patients with RA, IDO + DCs do not have sufficient immunosuppressive ability when WRS is overexpressed in T cells [ 88 , 89 , 90 ]. The activity of IDO is decreased, whereas WRS expression is increased in T cells from patients with immune thrombocytopenia (ITP) [ 91 ] and Graves’ disease [ 92 ], which are autoimmune disorders that result in platelet destruction and hyperthyroidism, respectively.…”

Section: Immunological Role Of Wrs In Trp Metabolismmentioning

confidence: 99%

Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target

Ahn

Zhou

et al. 2021

IJMS

View full text Add to dashboard Cite

Tryptophanyl-tRNA synthetase (WRS) is an essential enzyme that catalyzes the ligation of tryptophan (Trp) to its cognate tRNAtrp during translation via aminoacylation. Interestingly, WRS also plays physiopathological roles in diseases including sepsis, cancer, and autoimmune and brain diseases and has potential as a pharmacological target and therapeutic. However, WRS is still generally regarded simply as an enzyme that produces Trp in polypeptides; therefore, studies of the pharmacological effects, therapeutic targets, and mechanisms of action of WRS are still at an emerging stage. This review summarizes the involvement of WRS in human diseases. We hope that this will encourage further investigation into WRS as a potential target for drug development in various pathological states including infection, tumorigenesis, and autoimmune and brain diseases.

show abstract

Survival of lymphocytes is not restricted by IDO-expressing fibroblast from rheumatoid arthritis patients

Cited by 3 publications

References 45 publications

Research Progress of Therapeutic Enzymes and Their Derivatives: Based on Herbal Medicinal Products in Rheumatoid Arthritis

Research Progress of Therapeutic Enzymes and Their Derivatives: Based on Herbal Medicinal Products in Rheumatoid Arthritis

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases

Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target

Contact Info

Product

Resources

About